Geode Capital Management LLC Buys 38,520 Shares of Cryoport, Inc. (NASDAQ:CYRX)

Geode Capital Management LLC boosted its stake in Cryoport, Inc. (NASDAQ:CYRX) by 3.6% in the 3rd quarter, Holdings Channel.com reports. The firm owned 1,097,369 shares of the company’s stock after acquiring an additional 38,520 shares during the quarter. Geode Capital Management LLC’s holdings in Cryoport were worth $8,902,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently added to or reduced their stakes in CYRX. Bullseye Asset Management LLC increased its holdings in shares of Cryoport by 58.7% during the third quarter. Bullseye Asset Management LLC now owns 214,264 shares of the company’s stock worth $1,737,000 after buying an additional 79,244 shares in the last quarter. Barclays PLC grew its holdings in Cryoport by 272.9% during the 3rd quarter. Barclays PLC now owns 81,417 shares of the company’s stock worth $660,000 after acquiring an additional 59,582 shares during the last quarter. State Street Corp raised its stake in shares of Cryoport by 2.8% during the third quarter. State Street Corp now owns 1,003,080 shares of the company’s stock valued at $8,135,000 after acquiring an additional 27,438 shares during the last quarter. Stifel Financial Corp raised its stake in shares of Cryoport by 11.0% during the third quarter. Stifel Financial Corp now owns 139,745 shares of the company’s stock valued at $1,133,000 after acquiring an additional 13,809 shares during the last quarter. Finally, Point72 Asset Management L.P. acquired a new position in shares of Cryoport during the third quarter worth $3,405,000. Institutional investors and hedge funds own 92.90% of the company’s stock.

Analyst Ratings Changes

CYRX has been the subject of several analyst reports. Guggenheim started coverage on Cryoport in a research report on Thursday, December 19th. They set a “buy” rating and a $11.00 target price for the company. Roth Mkm decreased their price target on Cryoport from $18.00 to $15.00 and set a “buy” rating for the company in a research note on Friday, November 8th. Finally, UBS Group lifted their price objective on Cryoport from $7.00 to $9.00 and gave the stock a “neutral” rating in a research note on Friday, October 18th. Three research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $12.29.

Cryoport Stock Down 0.9 %

Shares of Cryoport stock opened at $7.78 on Thursday. The stock’s 50-day moving average is $7.49 and its 200 day moving average is $7.85. Cryoport, Inc. has a one year low of $5.32 and a one year high of $20.10. The firm has a market cap of $384.57 million, a price-to-earnings ratio of -2.30 and a beta of 1.62. The company has a debt-to-equity ratio of 0.48, a current ratio of 5.70 and a quick ratio of 5.32.

Insiders Place Their Bets

In other Cryoport news, Director Ramkumar Mandalam sold 7,369 shares of Cryoport stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $7.46, for a total value of $54,972.74. Following the completion of the sale, the director now directly owns 59,497 shares of the company’s stock, valued at approximately $443,847.62. The trade was a 11.02 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Jerrell Shelton sold 50,000 shares of the stock in a transaction dated Tuesday, November 19th. The stock was sold at an average price of $6.78, for a total transaction of $339,000.00. Following the transaction, the chief executive officer now directly owns 712,747 shares in the company, valued at $4,832,424.66. This trade represents a 6.56 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 109,869 shares of company stock worth $735,673. 10.10% of the stock is owned by corporate insiders.

About Cryoport

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.